Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Testosterone Treatment for Fatigue in Men With Multiple Sclerosis
NCT03000127Phase 2Withdrawn
- Sponsor
- University of California, Los Angeles
- Start
- Jul 2018
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-blind, single-arm trial of AndroForte in multiple sclerosis (MS), sponsored by University of California, Los Angeles. Primary endpoint: Modified Fatigue Impact Scale at 18 months. Planned start Jul 2018; status: withdrawn.
02
Drugs
AndroForte
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT03000127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03000127.